Bruce Goldsmith, outgoing Passage Bio CEO

Pas­sage Bio CEO de­parts af­ter March lay­offs as biotech goes with le­gal chops for in­ter­im re­place­ment

Pas­sage Bio’s am­bi­tions will be han­dled by a new face go­ing for­ward as Bruce Gold­smith ex­it­ed Tues­day, adding to the list of biotechs fac­ing the un­re­lent­ing bear mar­ket that has forced lead­er­ship shuf­fles to hap­pen at break­neck speed.

The biotech said the May 31 sep­a­ra­tion was a “mu­tu­al agree­ment be­tween the Board and Dr. Gold­smith,” ac­cord­ing to an SEC fil­ing.

Gold­smith is leav­ing his CEO, pres­i­dent and board posts at the Jim Wil­son gene ther­a­py mak­er just months af­ter the biotech laid off 13% of its work­force. Al­so in March, R&D chief Eliseo Sali­nas quit as did board mem­ber Liam Rat­cliffe, who dis­agreed with the biotech’s “busi­ness plans and op­er­a­tions.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.